| URL | https://www.fiercepharma.com/manufacturing/amgen-l |
| Source | Fierce Pharma |
| Date Published | 09/26/2025 |
| Author Name | Eric Sagonowsky |
| Company/Division name | Amgen |
| Parent company | Amgen Inc |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2025 |
| Capital investment ($): | 650 |
| Country(ies) from which reshored: | Puerto Rico |
| City reshored to: | Juncos |
| State(s) reshored to: | PR |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharma |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Lead time/Time to market, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market |